HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjuvant chemotherapy in stage I and stage II testicular cancer.

Abstract
Adjuvant chemotherapy in low-stage testis cancer is an accepted treatment option for two clinical situations: (1) chemotherapy after complete removal of the primary tumor by orchidectomy without clinical evidence of metastasis (clinical stage I), and (2) chemotherapy after complete surgical removal of non-seminomatous retroperitoneal metastases up to 5 cm in greatest transverse diameter by retroperitoneal lymph node dissection in clinical stage II. Aim of treatment is the prevention of tumor recurrences. The risk of recurrence depends on the type and stage of disease and ranges from 16% (clinical stage I seminoma) to 50% (pathological stage II B non-seminoma). Thus, 50-84% of patients receive adjuvant treatment unnecessarily. Prognostic factors have been developed in each tumor entity to tailor treatment to patients with high risk of recurrence.
AuthorsP Albers, F G Perabo, D Melchior, R Siener
JournalWorld journal of urology (World J Urol) Vol. 19 Issue 2 Pg. 76-81 (Apr 2001) ISSN: 0724-4983 [Print] Germany
PMID11374321 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Carboplatin
Topics
  • Antineoplastic Agents (therapeutic use)
  • Carboplatin (therapeutic use)
  • Chemotherapy, Adjuvant
  • Humans
  • Male
  • Neoplasm Staging
  • Seminoma (drug therapy, pathology)
  • Testicular Neoplasms (drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: